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Multiple endocrine neoplasia 
Paul J Newey 
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endocrine disorders. Competing interests: he has received speaker and/or consultancy fees from Ipsen, 
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Key Points 
• The possibility of multiple endocrine neoplasia (MEN) should be considered in all patients presenting
with apparently sporadic MEN-associated tumours, and a detailed family history obtained to
establish evidence of a hereditary disorder
• Genetic testing should be offered to all individuals with a likely clinical diagnosis of MEN1 or MEN2
(i.e. MEN1 and RET mutational analysis, respectively). For MEN2, this includes all patients with
medullary thyroid cancer (MTC). Genetic testing should be offered to all first-degree relatives of
affected individuals
• Patients at risk of developing MEN1 (i.e. MEN1 mutation carriers) should be offered periodic clinical,
biochemical and radiological screening to enable the early detection of tumours
• Patients at risk of developing MEN2 (i.e. RET mutation carriers) should be undergo periodic clinical,
biochemical and radiological evaluation, and, where appropriate, be offered early prophylactic
thyroidectomy, according to the risk category of RET mutation
• Treatment of MEN1 and MEN2 should aim to minimize the morbidity and mortality associated with
disease, while maintaining the patient’s quality of life. Management is often complex and requires
multidisciplinary involvement
Keywords 
Genetic testing; hereditary disease; medullary thyroid cancer (MTC); pancreatic neuroendocrine tumour; 
parathyroid tumour; phaeochromocytoma; pituitary adenoma 
Abstract  
Multiple endocrine neoplasia (MEN) describes the occurrence of tumours affecting two or more endocrine 
glands in one patient. Two main forms are recognized: MEN type 1 (MEN1) and type 2 (MEN2). MEN1 is 
characterized by the combined occurrence of parathyroid, pituitary and pancreatic neuroendocrine tumours, 
whereas MEN2 features medullary thyroid cancer in association with phaeochromocytoma and parathyroid 
tumours. Although both MEN1 and MEN2 are autosomal dominant disorders, they have contrasting 
molecular aetiologies: MEN1 results from inactivating germline mutations of the MEN1 tumour suppressor 
gene, whereas MEN2 results from activating mutations in the RET proto-oncogene. The clinical features 
arising of each relate to the location of tumour development and/or hormonal hypersecretion, while treatment 
approaches aim to minimize morbidity and mortality, and preserve quality of life. Genetic testing is a key 
component of management, not only to confirm the diagnosis in affected patients, but also to identify family 
members who are at risk of disease but may be asymptomatic. It is recommended that patients ‘at risk’ of 
developing MEN1 and MEN2 (i.e. mutation carriers) undergo periodic clinical, biochemical and radiological 
surveillance to enable the early identification and/or treatment of tumours. Here, a brief overview of MEN1 
and MEN2 is provided. 
© <2017>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://
creativecommons.org/licenses/by-nc-nd/4.0/ 
This is the accepted manuscript, final version available via DOI:10.1016/j.mpmed.2017.06.007
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Multiple endocrine neoplasia type 1 (MEN1) 
Definitions and epidemiology 
MEN1 is characterized by the combined occurrence of parathyroid, pituitary and duodenopancreatic 
neuroendocrine tumours. A spectrum of additional tumours is reported, including thymic and bronchial 
carcinoids, adrenocortical tumours, and tumours affecting the skin and soft tissues (Table 1). The diagnosis 
of MEN1 can be established clinically (i.e. patient with ≥2 relevant endocrine tumours) or genetically (i.e. an 
individual with or without clinical manifestations harbouring an MEN1 mutation).1 The estimated incidence is 
approximately 1 in 30,000. It is associated with premature mortality, with around 30–70% of affected patients 
dying from causes related to the disorder. 
 
Pathology and pathogenesis 
MEN1 is an autosomal dominant disorder caused by germline mutation of the MEN1 gene, such that first-
degree relatives of an affected individual have a 50% chance of inheriting the MEN1 mutation. However, in 
around 5–10% of cases, the MEN1 mutation occurs de novo so an affected individual has unaffected 
parents. The MEN1 gene is located at chromosome 11q13.1 and encodes the protein menin. Most MEN1 
mutations result in loss of menin function (e.g. nonsense or frameshift mutations), while MEN1-associated 
tumours typically demonstrate bi-allelic MEN1 inactivation consistent with a tumour suppressor function. 
Although menin is reported to influence many cellular processes (e.g. activation and repression of gene 
transcription, modulation of cellular signalling pathways), the molecular mechanisms leading to 
tumourigenesis remain ill-defined.  
 
Disease course 
MEN1 is a highly penetrant disorder with virtually all patients (>98%) expressing disease by the fifth decade. 
However, no genotype–phenotype correlation exists, so it is not possible to predict the onset or spectrum of 
tumours in a given individual. Symptomatic presentations are unusual in early childhood (e.g. <10 years of 
age), although the earliest reported cases of MEN1-associated hyperparathyroidism, pituitary adenoma and 
pancreatic neuroendocrine tumour (PNET) are at 4, 5 and 5 years of age, respectively.1,2 By 21 years of age, 
the penetrance of these tumours is reported to reach approximately 75%, 35% and 20–25%, respectively.2 
Hyperparathyroidism is often the first manifestation of disease, although a minority present with a PNET, 
pituitary tumour or other MEN1-associated tumour (e.g. thymic carcinoid).2 
 
Clinical features and treatment 
Parathyroid tumours: primary hyperparathyroidism occurs in >95% of MEN1 patients, demonstrates an 
equal sex distribution, and typically manifests synchronous or asynchronous involvement of all four glands. 
Patients are frequently asymptomatic with mild hypercalcaemia, although symptomatic disease can occur 
and relates to hypercalcaemia (e.g. thirst, polyuria, constipation) or disease complications (e.g. 
nephrolithiasis, osteitis fibrosa cystica). Surgery is the treatment of choice, with most experts advocating 
subtotal (i.e. removal of ≥3.5 glands) or total parathyroidectomy.1 
 
Pituitary tumours: the incidence of pituitary tumours in MEN1 is estimated to be 30–40%, with most 
occurring as microadenomas (<1 cm diameter). Prolactinomas represent the most common functioning 
tumour, although somatotropinomas and corticotropinomas also occur. The remainder comprise clinically 
non-functioning adenomas. Symptoms relate to hormonal hypersecretion or local mass effects (e.g. 
hypopituitarism, visual field defect). Treatment is the same as for sporadic counterparts (e.g. trans-
sphenoidal surgery, dopamine agonist for prolactinoma). 
 
Pancreatic neuroendocrine tumours: clinically significant PNETs occur in around 30–80% of patients with 
MEN1 and are the leading cause of premature mortality. Patients can harbour multiple tumours, and 
attempts to correlate imaging findings with symptoms and/or biochemical evidence of hormone 
hypersecretion can be confounded.3 
Functioning tumours – gastrinomas occur in 30–40% of patients with MEN1. Untreated, they are 
associated with gastric acid hypersecretion, recurrent peptic ulceration and haemorrhage (Zollinger–Ellison 
syndrome). Most MEN1-associated gastinomas are small (<1 cm) and multiple, and occur in the duodenal 
mucosa. Surgical resection of duodenal gastrinomas is controversial as good long-term outcomes are 
reported with medical therapy alone (e.g. proton pump inhibitors).3 Insulinomas affect 10–30% of MEN1 
patients and often occur at a young age (around 10–15% penetrance by 21 years of age). Typically, they 
present with symptomatic hypoglycaemia, and curative surgery is the treatment of choice. Other functioning 
PNETs (e.g. glucagonomas, VIPomas) occur rarely. 
Non-functioning PNETs (NF-PNETS) – these are recognized as the most common PNETs in MEN1, 
occurring in 30–60% of individuals. Presentations in early childhood are rare, but recent series indicate a 
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prevalence of 10–40% by around 20 years of age. Diagnosis typically relies on imaging (e.g. endoscopic 
ultrasound, magnetic resonance imaging) as patients are often asymptomatic and tumour markers (e.g. 
chromogranin A) unreliable.3 The risk of metastatic disease is related to tumour diameter, with most 
clinicians recommending surgery for NF-PNETS of >2 cm, although some advocate lower cut-offs.1,3 
Systemic therapies (e.g. somatostatin analogues, tyrosine kinase inhibitors) and locoregional approaches 
(e.g. cytoreductive surgery, radiofrequency ablation) are used for advanced disease. 
 
Other MEN1-associated tumours: adrenocortical tumors occur in approximately 20% of patients. Most are 
small (<1 cm) and non-functioning, although a minority are hormone-secreting (e.g. resulting in primary 
hyperaldosteronism or Cushing’s syndrome). Adrenocortical carcinoma is occasionally reported. Thymic and 
bronchial carcinoid tumors occur in 2–8% of patients with MEN1. Thymic carcinoids, occurring predominantly 
in men, are associated with an aggressive disease course, while bronchial carcinoids have more favourable 
outcomes. 
 
Genetic testing 
MEN1 genetic testing should be offered to all patients with a clinical diagnosis of MEN1, all first-degree 
relatives of affected individuals (symptomatic and asymptomatic), and individuals with an increased 
likelihood of disease (e.g. multiple PNETs, sporadic gastrinoma, recurrent or multigland parathyroid 
disease). Establishing a genetic diagnosis of MEN1 is important for several reasons: first, to confirm the 
clinical diagnosis; second, to facilitate the identification of first-degree relatives who carry the MEN1 
mutation; and finally, to identify family members who do not harbour the mutation and can be reassured. 
Notably, around 5–10% of patients with MEN1 do not have mutations in the MEN1 coding region; these 
individuals can harbour mutations in non-coding regions or mutations in other genes. For example, a small 
number of kindreds with an MEN1-like phenotype have been identified to harbour mutations in the cyclin-
dependent-kinase inhibitor 1B (CDKN1B) gene, a condition referred to as MEN type 4. 
 
Organization of care and screening  
Individuals with a clinical or genetic diagnosis of MEN1 should be cared for by a multidisciplinary team with 
appropriate expertise. Current guidelines recommend that individuals at high risk of disease (i.e. MEN1 
mutant gene carriers) undergo periodic clinical, biochemical and radiological screening to identify tumours at 
an early stage (Table 2). Given the potential complexities of management, the patient (or relevant carer) 
should be involved in decisions regarding care. 
 
Multiple endocrine neoplasia type 2 (MEN2) 
Definition and epidemiology 
MEN2 is characterized by the occurrence of medullary thyroid carcinoma (MTC), together with 
phaeochromocytoma and parathyroid adenomas. MEN2 is categorized into two main syndromes: MEN2A 
and MEN2B. MEN2A accounts for 90–95% of cases and describes MTC in association with 
phaeochromocytoma and parathyroid tumors, although some families only manifest MTC (i.e. ‘familial MTC’). 
MEN2B is less frequent, representing around 5–10% of MEN2 cases. It describes MTC and 
phaeochromocytoma in association with a marfanoid habitus, mucosal neuromas, medullated corneal fibres 
and intestinal autonomic ganglion dysfunction. Collectively, the reported incidence of MEN2 is 1 in 80,000 
live births. 
 
Pathology and pathogenesis 
MEN2 is an autosomal dominant disorder resulting from germline mutations in the rearranged during 
transfection (RET) proto-oncogene (located at chromosome 10q11.2), which encodes a tyrosine kinase 
receptor expressed in neural crest cells (e.g. thyroid C cells, adrenal medullary cells).4 MEN2 can occur in 
the absence of affected family members as de novo RET mutations are observed in around 5–10% and 
around 75% of MEN2A and MEN2B cases, respectively. Most cases of MEN2A result from missense 
substitutions affecting one of a small number of highly conserved cysteine residues, while around 95% of 
individuals with MEN2B harbour a methionine to threonine substitution affecting codon 918 (Figure 1). Thus, 
MEN2 displays a strong genotype–phenotype correlation such that the specific RET mutation predicts the 
timing and behavior of MTC and the occurrence of associated endocrine manifestations (Table 3).5 
 
Clinical features  
Medullary thyroid carcinoma: MTC, arising from thyroid parafollicular C cells, is highly penetrant in MEN2 
(70–100% of patients) and remains the major determinant of premature mortality.4,5 Typically, MTC is the 
first manifestation of disease in MEN2A, affected individuals presenting with a neck mass. Additional 
symptoms can include diarrhoea and or flushing, while lymph node and distant metastases often occur at 
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presentation. The diagnosis of MTC is based on the demonstration of high serum calcitonin concentrations 
combined with appropriate radiological and/or cytological evidence of tumour occurrence. Where possible, 
curative surgical resection is the treatment of choice. For patients with advanced disease, external-beam 
radiotherapy, radionuclide therapy and tyrosine kinase inhibitors are used. 
 
Phaeochromocytoma: this can occur in individuals with MEN2A and MEN2B. In MEN2A, it typically 
presents in the third or fourth decade, with symptoms of catecholamine excess including episodic sweating, 
palpitations, headache and anxiety. The diagnosis and treatment of phaeochromocytoma is the same as for 
sporadic disease, although the possibility of bilateral disease should be considered.  
 
Primary hyperparathyroidism: a minority of MEN2A patients develop primary hyperparathyroidism, which 
is often mild. Several glands can be affected, with treatment aimed at removal of enlarged glands. 
 
Genetic testing: indications and implications  
Germline RET genetic testing should be performed in all patients with a clinical diagnosis of MEN2 or 
apparently sporadic MTC or phaeochromocytoma, as well as in first-degree relatives of known RET mutation 
carriers. The ability to make a genetic diagnosis of MEN2, often in early childhood, before the onset of 
clinical features, enables the appropriate monitoring and treatment of asymptomatic individuals. Prophylactic 
thyroidectomy is typically recommended in early childhood for those ‘at risk’ of developing hereditary MTC 
(i.e. RET mutation carriers), although the timing of surgery varies according to the risk category of RET 
mutations (Table 3).5 Screening for phaeochromocytoma and hyperparathyroidism is also recommended 
(Table 3).5  
  
 5 
KEY REFERENCES 
1. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 
1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990–3011. 
2. Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort 
study from the Groupe d'etude des Tumeurs Endocrines. J Clin Endocrinol Metab 2015; 100: 1568–77. 
3. Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic 
neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol 2015; 3: 895–905.  
4. Waguespack SG, Rich TA, Perrier ND, Jimenez C, Cote GJ. Management of medullary thyroid carcinoma 
and MEN2 syndromes in childhood. Nat Rev Endocrinol 2011; 7: 596–607. 
5. Wells SA, Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the 
management of medullary thyroid carcinoma. Thyroid 2015; 25: 567–610. 
  
 6 
Table 1 Clinical features of MEN1 
Primary hyperparathyroidism (>95%) 
• Parathyroid adenoma/hyperplasia (>95%) 
• Parathyroid carcinoma (very rare) 
Pancreatic neuroendocrine tumours (PNETs) 
(30–80%) 
• Gastrinomaa (30–40%) 
• Insulinoma (10–30%) 
• Glucagonoma (<3%) 
• VIPoma (very rare) 
• Non-functioning PNET (30–60%) 
Pituitary adenomas (30–40%) 
• Prolactinoma (20%) 
• Somatotropinoma (<10%) 
• Corticotropinoma (<5%) 
• Non-functioning adenoma (10–25%) 
Foregut neuroendocrine tumours (NETs) 
• Thymic NET (2–8%) 
• Bronchial NET (<5%) 
• Gastric NET (‘ECLoma’b) (10%) 
Adrenocortical tumours (10–20%) 
• Conn’s adenoma (around 1%) 
• Cortisol-secreting adenoma (around 1%) 
• Phaeochromocytoma (very rare) 
• Non-functioning adenoma (10–20%) 
• Adrenocortical carcinoma (around 1%) 
Miscellaneous tumours 
• Lipomas (30%) 
• Angiofibromas (85%) 
• Collagenomas (70%) 
• Meningiomas (around 5%) 
• Ependymomas (<5%) 
• Breast cancer (increased relative risk 
reported) 
aMost gastrinomas are located in the duodenal mucosa. 
b‘ECLoma’ refers to tumours arising from enterochromaffin-like cells, which are observed in patients with 
hypergastrinaemia caused by Zollinger–Ellison syndrome. 
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Table 2 Suggested screening guidelines for individuals at risk of MEN1 
 
MEN1-associated 
tumour 
 
Age to 
begin 
screening 
(years) 
Biochemical screening test 
(annually) 
Imaging screening 
test  
(time interval) 
Parathyroid  8 Calcium, PTH None 
Pancreatic     
Gastrinoma 20 Fasting gastrin  None 
Insulinoma 5 Fasting glucose (± insulin) None 
Other PNET  
 (e.g. non-functioning) 
10 Chromogranin A, gastrointestinal 
hormone profilea (e.g. glucagon, 
pancreatic polypeptide vasoactive 
intestinal peptide)  
MRI abdomen, EUS 
(annually) 
Pituitary     
Prolactinoma 5 Prolactin None 
Somatotropinoma 5 Insulin-like growth factor 1  None 
Other pituitary adenoma 
 (e.g. non-functioning 
NET) 
10b None, unless signs or symptoms of 
functioning tumour (e.g. corticotroph 
adenoma) 
MRI pituitary 
(every 3 years) 
Adrenocortical  <10 None, unless signs or symptoms of 
functioning tumour or tumour >1 cm 
on imaging 
MRI abdomen 
(annually) 
Thymic/bronchial 
carcinoid 
15 None CT or MRI chest  
(every 1–2 years) 
aAlthough chromogranin A, pancreatic polypeptide and glucagon concentrations can be elevated with NF-
PNETs, they have low sensitivity and specificity such that their value is debated.  
b Although pituitary tumours are reported in MEN1 patients as young as 5 years of age, in the absence of 
symptoms, signs or biochemical evidence of a pituitary adenoma, pituitary imaging may be delayed until >10 
years of age to coincide with pancreatic imaging. 
CT, computer tomography; EUS, endoscopic ultrasound; MRI, magnetic resonance imaging; PTH, 
parathyroid hormone.  
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Table 3 Suggested screening and treatment guidelines for individuals at risk of MEN2  
  American Thyroid Association MTC risk category of RET 
mutationa 
  Highest High Moderate 
 Relevant RET mutations Met918Thr Codon 634 
mutations 
Ala883Phe 
All other validated 
pathogenic 
mutations 
R
ec
om
m
en
de
d 
ag
e 
to
 
co
m
m
en
ce
 s
cr
ee
ni
ng
 / 
un
de
rt
ak
e 
in
te
rv
en
tio
n 
RET genetic testing ASAP and by <1 
year 
<3 years <3-5 years 
    
MTC    
First serum calcitonin/neck 
ultrasound 
ASAP (by <0.5–1 
year) 
3 years 5 years 
Prophylactic thyroidectomy ASAP (by <1 year) 5 years or earlier >5 years 
    
Phaeochromocytoma  11 years 11 years 16 years 
Primary 
hyperparathyroidism  
– 11 years 16 years 
aRisk category of RET mutation and screening and treatment schedule based on the Revised American 
Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma.5 
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Figure 1 
 
 
 
 
RET receptor structure and location of common MEN2-associated RET mutations. The RET receptor is a 
membrance-associated tyrosine kinase receptor expressed in cells of neural crest origin. MEN2-associated 
mutations arise most frequently in the cysteine-rich region of the extracellular domain, or in the intracellular 
domain associated with intrinsic tyrosine kinase activity, resulting in enhanced receptor signalling. RET 
mutations are described according to the respective missense substitution, with amino acids represented 
using standard nomencalture. The American Thyroid Association5 risk category of each RET mutation is 
represented by colour; red, ‘highest’ risk; blue, ‘high’ risk; green, ‘moderate ‘risk. Mutations associated with 
MEN2B are noted in parentheses.  
 10 
TEST YOURSELF 
To test your knowledge based on the article you have just read, please complete the questions below. The 
answers can be found at the end of the issue or online here. 
 
Question 1 
A 43-year old man presented  with biochemical evidence of hyperparathyroidism. Initial investigations with 
neck ultrasound and parathyroid sestamibi scan indicated a single right-sided parathyroid adenoma. He 
underwent curative surgery with the removal of a right inferior parathyroid adenoma. There were no other 
clinical symptoms or signs of additional endocrine disease, and no other past medical history of note. 
 
Which of the following should be performed initially to investigate  the possibility of multiple 
endocrine neoplasia? 
A. Germline MEN1 genetic testing. 
B. Germline RET genetic testing. 
C. Biochemical evaluation for likely tumours  
D. Take a relevant family history  
E. MR scan of pituitary and abdomen, CT scan of chest  
 
Answer: D. In the absence of a relevant family history, the likelihood of MEN1 or MEN2 in the setting of an 
apparently sporadic single parathyroid adenoma presenting in an individual >30 years of age is low. 
Furthermore, MEN1 is typically associated with multigland parathyroid disease, whereas primary 
hyperparathyroidism occurs in a minority of patients with MEN2A and is not a feature of MEN2B. Therefore 
routine genetic testing for MEN (MEN1 or RET) is not routinely indicated in adults (e.g. >30 years of age) 
with a solitary parathyroid adenoma in the absence of other relevant clinical features and/or family history. 
However, MEN1 genetic testing is indicated for children and young people presenting with primary 
hyperparathyroidism, as the likelihood of a genetic cause increases in this age group. In addition, genetic 
testing for MEN may be indicated in adults with recurrent or multi-gland parathyroid disease. Furthermore, in 
the scenario above, in the absence of a relevant family history, or signs or symptoms of associated 
endocrine disease, undertaking biochemical or radiological evaluation for MEN-associated tumours would 
not be indicated.   
 
Question 2 
A 26-year old woman presented  with amenorrhea and reduced libido. Her father and older brother had  a 
clinical diagnosis of MEN1 and carried a known pathogenic MEN1 mutation. The patient had not undergone 
genetic testing previously.  Clinical examination was normal 
 
Investigations 
Serum prolactin 1600 mU/L (<360) 
MR scan showed a pituitary microprolactinoma. 
 
What advice shouldbe given about genetic testing? 
A. No genetic testing is required as she hasalmost certainly inherited the MEN1 mutation from her 
father 
B. Germline testing of the whole MEN1 gene should be performed as she may have a different MEN1 
mutation t from her father and brother 
C. Germline MEN1 genetic testing should be performed but limited to determining  whether the patient 
harbours the same mutation as  her father and brother 
D. Genetic testing for a panel of genes associated with pituitary tumours including MEN1 should be 
performed to evaluate for other potential hereditary conditions 
E. Genetic testing for MEN1 should be undertaken, but only if there is evidence of primary 
hyperparathyroidism  
 
Answer: C. All patients at high risk of MEN1 should be offered genetic testing. This includes all first-degree 
relatives of known mutation carriers, whether they are symptomatic or asymptomatic. For example, here it is 
possible that the patient has a sporadic pituitary tumour, thereby representing a ‘phenocopy’ for MEN1. This 
describes the occurrence of clinical features characteristic of a given genotype (e.g. MEN1) but with a 
different aetiology (e.g. sporadic tumour). Such phenocopies are estimated to occur in approximately 10% of 
families with MEN1. In the case above, negative genetic testing will provide the patient reassurance that she 
has no increased risk of developing further MEN1-associated tumours or passing the mutation on to her 
children, whereas a positive test will establish the need for continuing MEN1 surveillance.  
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Question 3 
A 40-year man with  MEN1  attended for annual review in the endocrine clinic. He reported some indigestion 
controlled on treatment.. He had a  previous history of primary hyperparathyroidism treated with subtotal 
parathyroidectomy. He was taking  omeprazole 20 mg orally daily  Clinical examination was normal 
 
Investigations 
Serum corrected calcium 2.40 mmol/L (2.20–2.60) 
Plasma gastrin 105 pmol/L (<55)    
The remainder of the biochemistry was normal including chromogranin A, . glucagon, pancreatic polypeptide.  
MRI imaging showed a  0.9cm tumour in the tail of the pancreas not present on a scan 2 years previously 
 
 
What is the best  interpretation  and  management plan? 
 
A. The pancreatic abnormality is likely to be a gastrinoma, and the dose of omeprazole should be 
increased to 20mg twice a day. 
B. He needs immediate referral for surgery as there is a high risk of malignancy associated with the 
pancreatic neuroendocrine tumour (PNET)  
C. The normal concentrations of chromogranin A, pancreatic polypeptide and glucagon concentrations 
suggest this is unlikely to be a PNET, and pancreatic imaging should be repeated in 1 year 
D. The abnormality in the pancreas most likely represents a non-functioning PNET and should be 
reimaged in a further 3–6 months 
E. Somatostatin analogue therapy (e.g. octreotide) should be started as the abnormality most likely 
represents a pancreatic neuroendocrine tumour and may undergo regression 
 
 
Correct Answer: D. Most gastrinomas in MEN1 are small and occur in the duodenal mucosa. The modest 
elevation of gastrin in this case may reflect an underlying gastrinoma, but is more likely to be a consequence 
of proton pump inhibitor therapy, which is associated with hypergastrinaemia (A. Chromogranin A and other 
gut hormones (e.g. pancreatic polypeptide, glucagon) have a low sensitivity and specificity for detecting 
pancreatic neuroendocrine tumours (PNETs) (C). In the absence of other symptoms (e.g. hypoglycaemia), 
the abnormality in the tail of the pancreas is most likely to represent a non-functioning PNET, which is the 
most common PNET in MEN1. The risk of malignancy is associated with tumour diameter, with surgery 
typically recommended for tumours >2 cm (B).. However, repeat imaging after 3–6 months is recommended 
as an increase in size over a short interval favours earlier intervention. Somatostatin analogue therapy is 
typically reserved for patients with locally advanced or metastatic PNETs, or larger tumours unsuitable for 
resection (E) 
.  
.  
 
